Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 3/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.32 |
| ▸ | CDK1 | P06493 | 2/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9943148 | 0.84 | BCHE (0.34) | FFAR4 | |
| SCHEMBL9943104 | 0.82 | FFAR4 (0.37) | FFAR4KMT2A | |
| SCHEMBL9928254 | 0.79 | CDK5 (0.39) | CDK5CDK5R1GSK3BCDK1CCNB1 | |
| SCHEMBL9943124 | 0.79 | FFAR4 (0.32) | FFAR4 | |
| SCHEMBL9928252 | 0.77 | CDK5 (0.39) | CDK5CDK5R1GSK3BCDK1CCNB1 | |
| SCHEMBL9928255 | 0.75 | CDK5 (0.37) | CDK5CDK5R1GSK3BCDK1CCNB1 | |
| SCHEMBL10070478 | 0.71 | CDK5 (0.33) | CDK5CDK5R1GSK3BCDK1CCNB1 | |
| SCHEMBL9928253 | 0.69 | ALDH1A1 (0.35) | CDK5CDK5R1GSK3BCDK1CCNB1 | |
| SCHEMBL9928249 | 0.68 | FFAR4 (0.38) | FFAR4KMT2A | |
| SCHEMBL9928250 | 0.66 | FFAR4 (0.36) | CDK5CDK5R1GSK3BCDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120145974-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145974-A1 | CHROMENE COMPOUND | CRY2, CYP2J2, NR0B2 | CDK5 765/4885CDK5R1 299/4885GSK3B 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.